A 65-year-old woman with a history of myocardial infarction 2 years ago and recurrent angina despite atorvastatin 80 mg daily presents with LDL cholesterol of 95 mg/dL and triglycerides of 280 mg/dL. She has no contraindications to additional therapy. Which agent should be added to further reduce her atherosclerotic burden and cardiovascular risk?

Explanation

## Rationale for Ezetimibe as Second-Line Agent **Key Point:** When statin monotherapy fails to achieve LDL goal (target <70 mg/dL in secondary prevention), ezetimibe is the preferred second-line agent. It has proven cardiovascular benefit when added to statins and is cost-effective, well-tolerated, and guideline-recommended. ### Clinical Context: This Patient's Lipid Profile - **LDL 95 mg/dL** on atorvastatin 80 mg = above secondary prevention goal (<70 mg/dL) - **Triglycerides 280 mg/dL** = elevated but not the primary driver of ASCVD in secondary prevention - **Indication:** Requires intensification of LDL-lowering therapy ### Mechanism of Ezetimibe Ezetimibe inhibits Niemann-Pick C1-like 1 (NPC1L1) protein in the small intestine, blocking cholesterol absorption: 1. Reduces intestinal cholesterol uptake by ~50% 2. Increases hepatic LDL receptor expression (synergistic with statin) 3. Lowers LDL by an additional 15–20% when added to statin 4. Well-tolerated with minimal drug interactions ### Evidence for Ezetimibe + Statin **High-Yield:** The IMPROVE-IT trial (2015) demonstrated that ezetimibe added to simvastatin in post-ACS patients reduced cardiovascular events by 6% compared to statin alone, with a 24% relative risk reduction in the composite endpoint. This is the landmark trial supporting ezetimibe in secondary prevention. ### Comparison of Second-Line Agents for LDL Reduction | Agent | LDL Reduction | Indication | Evidence | Tolerability | |-------|---------------|-----------|----------|-------------| | **Ezetimibe** | 15–20% | Statin inadequacy | IMPROVE-IT: proven CV benefit | Excellent | | **Fenofibrate** | 5–15% | Hypertriglyceridemia | No CV benefit in statin-treated | GI upset, myopathy risk | | **Niacin** | 15–25% | Mixed dyslipidemia | AIM-HIGH, HPS2-THRIVE: no added benefit | Flushing, GI, hyperglycemia | | **Inclisiran** | 50–60% | Statin-intolerant or very high-risk | ORION trials: CV outcomes pending | Expensive, rare; not yet standard | **Clinical Pearl:** In this patient with recurrent angina despite statin therapy, the priority is LDL reduction to <70 mg/dL. Ezetimibe is the evidence-based next step. Triglycerides at 280 mg/dL are elevated but do not warrant fibrate monotherapy; if triglycerides remain high after ezetimibe, icosapent ethyl (high-dose EPA) may be considered if LDL is at goal. **Mnemonic:** **EZETIMIBE** = **E**xternal **Z**one **E**nteric **T**ransporter **I**nhibitor **M**akes **I**ncremental **B**enefit **E**vident (in secondary prevention). ## Why Ezetimibe Is Preferred Over Alternatives - Proven cardiovascular benefit in IMPROVE-IT (post-ACS population) - Additive LDL reduction without statin dose escalation - Excellent safety profile; no myopathy risk - Guideline-recommended as second-line by ACC/AHA and ESC - Cost-effective and widely available